Navigation Links
Today's Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
Date:7/18/2013

LONDON, July 18, 2013 /PRNewswire/ --

On Wednesday, July 17, 2013, shares in the healthcare sector ended mostly lower even as the broader market ended higher following positive news from Federal Reserve Chairman Ben Bernanke. The major movers in the sector included Delcath Systems Inc. (NASDAQ: DCTH), Astex Pharmaceuticals Inc. (NASDAQ: ASTX), BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com has completed their technical analysis on DCTH, ASTX, BMRN, and AKRX and these free reports are accessible by registering at:

http://www.aaaresearchreports.com/register/  

Shares in Delcath Systems Inc. moved lower on Wednesday, extending their losses for the week. The company's shares ended the day at $0.377, down 0.79%, after oscillating between $0.36 and $0.38. A total of 717,445 shares were traded which is less than its daily average volume of 1.61 million. In the last three months, Delcath's shares have fallen by 73.07% as compared to a gain of 8.31% in the S&P 500. Sign up for free technical research on DCTH at:

http://www.AAAResearchReports.com/DCTH071813.pdf

Astex Pharmaceuticals Inc.'s stock rose sharply on Wednesday, extending their gains for the week. The company's shares fluctuated between $5.48 and $5.70 before finishing the day 2.93% higher at $5.63. A total of 1.24 million shares were traded which is below the daily average volume of 1.57 million. Astex's shares have now gained 15.37% in the last one month, thus outperforming the S&P 500. However, in the last three months, the stock has fallen by 9.49%. Be sure to read our latest technical research on ASTX by registering at:

http://www.AAAResearchReports.com/ASTX071813.pdf

Shares in BioMarin Pharmaceuticals Inc. edged lower on Wednesday even as the broader market ended higher. The company's shares oscillated between $62.42 and $63.39 before closing the session 0.30% lower at $62.64. A total of 566,476 shares were traded which is less than its daily average volume of 1.38 million. The company's shares have gained 7.68% in the last one month as compared to a gain of 2.55% in the S&P 500. The stock has fallen by 3.35% and 1.63% in the last three trading sessions and the last three months, respectively, thus underperforming the S&P 500. Sign up and read the complimentary report on BMRN at:

http://www.AAAResearchReports.com/BMRN071813.pdf

Akorn Inc.'s stock closed 4.07% lower on Wednesday at $13.43 after fluctuating between $13.40 and $14.05. A total of 544,543 shares were traded which is slightly above the daily average volume of 541,382. The company's shares have fallen by 0.67% in the last one month, and 5.95% in the last three months, thus underperforming the S&P 500. The free report on AKRX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/AKRX071813.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.



'/>"/>
SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
2. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
3. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
4. Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration
5. Delcath To Present At Upcoming Investor Conferences
6. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
7. Delcath To Conduct Second Quarter 2012 Results Conference Call
8. Delcath To Present At JMP Securities Healthcare Conference On July 12
9. Delcath Announced Changes To Board Of Directors
10. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
11. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):